Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma

Cancer Immunology, Immunotherapy

Volumn 65, Issue 9, 2016, Pages 1015-1034

  Hoeller, Christoph ^a   Michielin, Olivier ^b,c   Ascierto, Paolo A ^d   Szabo, Zsolt ^e   Blank, Christian U ^f  

^a Universitatsklinik fur Dermatologie   (Austria)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e AMGEN INC   (United States)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Efficacy; GM CSF; Granulocyte macrophage colony stimulating factor; Immunotherapy; Melanoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE VACCINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; MELANOMA; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT DROPOUT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMIC THERAPY; PATHOLOGY; SKIN NEOPLASMS; TREATMENT OUTCOME;

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84976512956     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1860-3     Document Type: Review

References (83)

1. Ferlay J, Soerjomataram I,Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 26 Jan 2016
2. National Comprehensive Cancer Network (2015) NCCN Clinical Practice Guidelines in Oncology—Melanoma V3.2015. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed 22 May 2015
3. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G (2012) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii86–vii91. doi:10.1093/annonc/mds229
4. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G (2010) Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v194–v197. doi:10.1093/annonc/mdq188
5. NCCN (2009) NCCN Clinical Practice Guidelines in Oncology™. Melanoma V.2.2009. http://www.mmmp.org/mmmpFile/image/conv%20ther/NCCN%20guidelines_Melanoma.pdf. Accessed 5 Oct 2015
6. ® (aldesleukin) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf. Accessed 13 Oct 2015
7. Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA (2014) Novel approaches in melanoma prevention and therapy. Cancer Treat 159:443–455. doi:10.1007/978-3-642-38007-5_25
8. Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1–10. doi:10.1016/j.immuni.2013.07.012
9. ® highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf. Accessed 30 Nov 2015
10. ® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002213/WC500109299.pdf. Accessed 3 Aug 2015
11. Squibb BM (2015) OPDIVO (nivolumab) Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s002lbl.pdf. Accessed 12 Nov 2015
12. Squibb BM (2015) OPDIVO Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/003985/WC500189765.pdf. Accessed 3 Aug 2015
13. ® (pembrolizumab) highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf. Accessed 3 Aug 2015
14. Sharp M & Dohme Ltd. (2015) KEYTRUDA summary of product characteristics. http://ec.europa.eu/health/documents/community-register/2015/20150717132284/anx_132284_en.pdf. Accessed 5 Oct 2015
15. Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, Vasselli J, Ibrahim RA, Khleif S, Segal NH (2014) A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. J Clin Oncol 32:(suppl; abstr 3001^)
16. Shitara K, Yamada Y, Yoh K, Naito Y, Iwasa S, Yamamoto N, von Heydebreck A, Achiwa H, Doi T (2015) Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. J Clin Oncol 33:(suppl; abstr 3023)
17. Spira AI, K Park, Mazières J, Vansteenkiste JF, Rittmeyer A, Ballinger M, Waterkamp D, Kowanetz M, Mokatrin A, Fehrenbacher L (2015) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol. 33:(suppl; abstr 8010)
18. Amgen (2015) Imlygic™ highlights of prescribing information. http://pi.amgen.com/united_states/imlygic/imlygic_pi.pdf. Accessed 12 Nov 2015
19. Amgen (2015) Imlygic summary of product characteristics. Available from: https://www.medicines.org.uk/emc/medicine/31351. Accessed 26 Jan 2016
20. Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr (2014) Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2:11. doi:10.1186/2051-1426-2-11
21. Andtbacka RH, Kaufman HL, Collichio F et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788. doi:10.1200/JCO.2014.58.3377
22. Liu BL, Robinson M, Han ZQ et al (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10:292–303. doi:10.1038/sj.gt.3301885
23. Hwang TH, Moon A, Burke J et al (2011) A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 19:1913–1922. doi:10.1038/mt.2011.132
24. Burke JM, Lamm DL, Meng MV et al (2012) A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 188:2391–2397. doi:10.1016/j.juro.2012.07.097
25. Bramante S, Kaufmann JK, Veckman V et al (2015) Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. International journal of cancer. Int J Cancer 137:1775–1783. doi:10.1002/ijc.29536
26. Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chou J, Kaufman H (2015) Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 33:(suppl; abstr 9063)
27. Ribas A, Puzanov I, Gajewski T et al. (2015) A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB–IV melanoma. J Clin Oncol 33:(suppl; abstr TPS9081)
28. Shi Y, Liu CH, Roberts AI et al (2006) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Res 16:126–133. doi:10.1038/sj.cr.7310017
29. ® (sargramostim) prescribing information. http://products.sanofi.us/Leukine/Leukine.html. Accessed 26 Nov 2015
30. Gomez-Cambronero J, Horn J, Paul CC, Baumann MA (2003) Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol 171:6846–6855
31. Watnick RS (2012) The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a006676
32. Coffelt SB, Kersten K, Doornebal CW et al (2015) IL-17-producing gamma delta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522:345–348. doi:10.1038/nature14282
33. Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33:949–955. doi:10.1093/carcin/bgs123
34. Dolcetti L, Peranzoni E, Ugel S et al (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40:22–35. doi:10.1002/eji.200939903
35. Fernandez A, Oliver L, Alvarez R, Fernandez LE, Lee KP, Mesa C (2014) Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother 10:3251–3260. doi:10.4161/hv.29847
36. de Vries CR, Monken CE, Lattime EC (2015) The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther 22:154–162. doi:10.1038/cgt.2015.2
37. Burga RA, Thorn M, Point GR et al (2015) Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 64:817–829. doi:10.1007/s00262-015-1692-6
38. Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, Disis ML (2012) Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res 18:3122–3131. doi:10.1158/1078-0432.ccr-12-0113
39. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC, Singh RK, Hoke TA, Talmadge JE (2010) Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immun 59:47–62. doi:10.1007/s00262-009-0719-2
40. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S (2010) Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718–730. doi:10.1245/s10434-009-0809-6
41. Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM (2012) Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother 35:702–710. doi:10.1097/CJI.0b013e318272569b
42. Daud AI, Mirza N, Lenox B et al (2008) Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 26:3235–3241. doi:10.1200/jco.2007.13.9048
43. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L (2007) Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 8:226–232. doi:10.1093/annonc/mdl158
44. Jinushi M, Hodi FS, Dranoff G (2008) Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 222:287–298. doi:10.1111/j.1600-065X.2008.00618.x
45. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94
46. Celis E (2007) Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 110:203–214. doi:10.1002/cncr.22744
47. Grotz TE, Kottschade L, Pavey ES, Markovic SN, Jakub JW (2014) Adjuvant GM-CSF improves survival in high-risk stage IIIC melanoma: a single-center study. Am J Clin Oncol 37:467–472. doi:10.1097/COC.0b013e31827def82
48. Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H (2005) Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 54:208–218. doi:10.1007/s00262-004-0587-8
49. Hodi FS, Lee S, McDermott DF et al (2014) Ipilimumab plus sargramostim versus ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744–1753. doi:10.1001/jama.2014.13943
50. Markovic SN, Suman VJ, Ingle JN et al (2006) Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 29:352–360. doi:10.1097/01.coc.0000217877.78473.a4
51. Schaed SG, Klimek VM, Panageas KS et al (2002) T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8:967–972
52. Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP (2011) Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol 68:1081–1087. doi:10.1007/s00280-011-1703-z
53. O’Day SJ, Boasberg PD, Piro L et al (2002) Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8:2775–2781
54. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, Soong SJ (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 18:1614–1621
55. Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, Lin HY, Soong SJ (2009) Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother 32:632–637. doi:10.1097/CJI.0b013e3181a7d60d
56. Boasberg PD, Hoon DS, Piro LD et al (2006) Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 126:2658–2663. doi:10.1038/sj.jid.5700545
57. Fruehauf JP, Kong KM, Jakowatz JG (2005) Docetaxel and vinorelbine plus GM-CSF in malignant melanoma. Oncology 19:19–22
58. Groenewegen G, Bloem A, De Gast GC (2002) Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother 51:630–636. doi:10.1007/s00262-002-0323-1
59. Gunturu KS, Meehan KR, Mackenzie TA et al (2010) Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol 28:1196–1202. doi:10.1200/jco.2009.24.8153
60. Locke F, Clark JI, Gajewski TF (2010) A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma. Cancer Chemother Pharm 65:509–514. doi:10.1007/s00280-009-1057-y
61. Weber RW, O’Day S, Rose M et al (2005) Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol 23:8992–9000. doi:10.1200/jco.2005.02.5791
62. O’Day SJ, Atkins MB, Boasberg P et al (2009) Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol 27:6207–6212. doi:10.1200/jco.2008.20.3075
63. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E, Schadendorf D (2000) Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23:275–281
64. Bins A, Mallo H, Sein J, van den Bogaard C, Nooijen W, Vyth-Dreese F, Nuijen B, de Gast GC, Haanen JB (2007) Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J Immunother 30:234–239. doi:10.1097/01.cji.0000211333.06762.47
65. Adamina M, Rosenthal R, Weber WP et al (2010) Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther 18:651–659. doi:10.1038/mt.2009.275
66. Dillman RO, Selvan SR, Schiltz PM et al (2009) Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radio 24:311–319. doi:10.1089/cbr.2008.0599
67. Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S (2008) Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31:180–188. doi:10.1097/CJI.0b013e31815ce501
68. Pilla L, Patuzzo R, Rivoltini L et al (2006) A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 55:958–968. doi:10.1007/s00262-005-0084-8
69. Slingluff CL Jr, Petroni GR, Olson W et al (2008) Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973–4980. doi:10.1200/jco.2008.17.3161
70. Slingluff CL Jr, Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM (2013) A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 19:4228–4238. doi:10.1158/1078-0432.ccr-13-0002
71. Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588:368–376. doi:10.1016/j.febslet.2013.10.015
72. Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25. doi:10.1038/cdd.2013.67
73. Hervieu A, Rebe C, Vegran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G (2013) Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol 133:499–508. doi:10.1038/jid.2012.273
74. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A (2009) Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 69:6987–6994. doi:10.1158/0008-5472.can-09-1106
75. Byrne KT, Turk MJ (2011) New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2:684–694
76. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS (1998) Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034–1039. doi:10.1046/j.1523-1747.1998.00411.x
77. Slingluff CL Jr, Petroni GR, Olson WC et al (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036–7044. doi:10.1158/1078-0432.ccr-09-1544
78. Slingluff CL Jr (2011) The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J 17:343–350. doi:10.1097/PPO.0b013e318233e5b2
79. Tenbusch M, Kuate S, Tippler B, Gerlach N, Schimmer S, Dittmer U, Uberla K (2008) Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol 9:13. doi:10.1186/1471-2172-9-13
80. Ragnhammar P, Friesen HJ, Frodin JE, Lefvert AK, Hassan M, Osterborg A, Mellstedt H (1994) Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84:4078–4087
81. Mitchell DA, Sayour EJ, Reap E et al (2015) Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol Res 3:320–325. doi:10.1158/2326-6066.cir-14-0100
82. Meager A, Wadhwa M, Bird C, Dilger P, Thorpe R, Newsom-Davis J, Willcox N (1999) Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology 97:526–532
83. Lawson DH, Lee S, Zhao F et al (2015) Randomized, pPlacebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 33:4066–4076. doi:10.1200/jco.2015.62.0500